About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Better Reagent Offers Personalized Cancer Immunotherapies

by Mary Selvaraj on August 10, 2019 at 10:57 AM
Font : A-A+

Better Reagent Offers Personalized Cancer Immunotherapies

Stabilized form of tetramer reagent holds a lot of promise in a personalized protocol where disease-relevant T Cells are isolated and activated to use as a therapeutic product.

In the journal Science Immunology, researchers from DTU Health Technology and Jacobs University in Bremen have just published their cutting-edge research demonstrating advancement in detection of a certain type of immune cells, called T cells. Improved detection of T cells have several therapeutic implications.

Advertisement


For example, in cancer immunotherapy (a therapeutic approach that engage patients own immune cells) characterization of T cells that recognize cancer cells is crucial for tailoring personalized treatment strategies.

T cells are white blood cells of the immune system that have amazing properties: they can detect cancer cells and virus-infected cells in the body, and they even attack and eliminate these. This is why T cells constitute an essential part of the immune response, which patients mount, against tumors and viruses.
Advertisement

When applying immunotherapy an immune response against a tumor takes place, the tumor-fighting T cells in the blood of the patient multiply. To find out how well the immunotherapy is working, scientists and doctors want to check how many tumor-specific T cells a patient has mounted. The tumor-specific T cells are identified by their specific T cell receptor using a colored reagent called an MHC tetramer. Using this reagent, the tumor-specific T cells become visible and can be counted under the microscope or in a high-throughput machine called a flow cytometer.

Super-stable molecule

The MHC proteins of the MHC tetramer reagent were previously difficult to produce due to the inherent instability of the MHC protein, and that used to be a bottleneck in research and diagnosis.

"Whenever a researcher needed MHC tetramers, they had to ask a company to make them, and the process took four to six weeks", explains Prof. Sebastian Springer, Jacobs University Bremen.

"Of course, that created big problems if they had a sick patient they wanted to diagnose, or if they were following a really urgent scientific project. The problem was that every MHC protein contains a little piece of a tumor or virus called a peptide, which varies from one patient to the other, and without the peptide, the MHC protein was unstable and perished quickly, even if it was kept in the fridge, thereby destroying the MHC tetramer."

It is the development and use of a super-stable form of the MHC tetramer reagents that professor Sine Reker Hadrup, DTU Health Technology, and her collaborators at the Jacobs University Bremen in Germany, led by Prof. Sebastian Springer has published in Science Immunology. With the new invention, MHC molecules can be loaded with peptides instantly, on demand.

"The technology opens a range of new possibilities for tracking disease relevant T cells in patients and to manipulate T cells to specifically fight e.g. Cancer" says Sine Reker Hadrup.

Cause for a company

Hadrup and Springer have now co-founded a company named Tetramer Shop to produce and sell this innovative MHC tetramer reagent. The company has already seen significant interest, in its MHC tetramer reagents, from academia and pharma working on T cell immunotherapy as well as from various diagnostic platform companies.

Furthermore, Hadrup and Springer believes that the stabilized form of the MHC protein holds great promise within a new field of personalized T cell therapy, termed precision activated cell therapy, where patients own tumor-specific T cells, in a personalized protocol, are isolated and activated before being used as the therapeutic product.

This use could potentially give rise to yet another company.

Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Cancer News

Why Is Time of Day Important in Cancer Diagnosis and Treatment?
Chronotherapy (the sleep-wake cycle) is observed as a valuable alternative treatment in cancer diagnosis and treatment.
How Do Neutrophils Impact Pancreatic Cancer Treatment Resistance?
A nanoengineering platform targets neutrophils, the white blood cells without killing pancreatic cancer cells paving the way for effective treatments.
Lung Cancer: The Survival Advantage of Lobectomy Over Wedge Resection
The survival rates between lobectomy and wedge resection surgical procedures were found to be the same among lung cancer patients.
Could TKI Cancer Drugs Lead to Inflammatory Side Effects?
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Are Biomarkers the Key to Identifying Early Pancreatic Risk?
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Better Reagent Offers Personalized Cancer Immunotherapies Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests